v3.26.1
Net Loss Per Share - Schedule of Diluted Loss Per Share Anti-Dilutive (Details) - shares
 3 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Schedule of Diluted Loss Per Share Anti-Dilutive [Line Items]    
Antidilutive outstanding securities 58,975,671 15,297,443
Series A Warrant [Member]    
Schedule of Diluted Loss Per Share Anti-Dilutive [Line Items]    
Antidilutive outstanding securities 36,490,000
Series A Placement Agent Warrant [Member]    
Schedule of Diluted Loss Per Share Anti-Dilutive [Line Items]    
Antidilutive outstanding securities 3,649,000
Stock options [Member]    
Schedule of Diluted Loss Per Share Anti-Dilutive [Line Items]    
Antidilutive outstanding securities [1] 16 16
Restricted Stock Units [Member]    
Schedule of Diluted Loss Per Share Anti-Dilutive [Line Items]    
Antidilutive outstanding securities 3,838,750 15,906
Public warrants [Member]    
Schedule of Diluted Loss Per Share Anti-Dilutive [Line Items]    
Antidilutive outstanding securities 11,500,000 11,500,000
Private warrants [Member]    
Schedule of Diluted Loss Per Share Anti-Dilutive [Line Items]    
Antidilutive outstanding securities 18,892 19,180
Warrants issued along with redeemable promissory note [Member]    
Schedule of Diluted Loss Per Share Anti-Dilutive [Line Items]    
Antidilutive outstanding securities 5,297
Warrants issued in February 2026 private placement offering [Member]    
Schedule of Diluted Loss Per Share Anti-Dilutive [Line Items]    
Antidilutive outstanding securities 939
Warrants issued in November 2024 and December 2024 offering [Member]    
Schedule of Diluted Loss Per Share Anti-Dilutive [Line Items]    
Antidilutive outstanding securities 3,472,777 3,757,044
[1] In 2012, the Company adopted its 2012 Equity Incentive Plan, under which the Company may grant options and restricted stock to eligible participants. The plan is equity settled. Options are generally granted for a term of ten years. Options have a graded vesting period of up to four years and the expenses are recorded on a straight-line basis over the requisite service period for each separately vesting portion of the awards. The Company cancelled certain outstanding options at the time of Reverse Recapitalization. The remaining 16 fully vested options were assumed by the Company on the Reverse Recapitalization date, exercisable at exercise price ranging from $120 to $300.